Table of Contents
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Phase
1.2.3. Indication
1.2.4. Service Type
1.2.5. Sponsor
1.3. Regional Scope
1.4. Estimates And Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Bottom-up Approach
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
1.12. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of new technology in clinical research
3.2.1.2. Shift toward personalized medicine
3.2.1.3. Growing disease variation and prevalence
3.2.1.4. Growth in CRO market
3.2.2. Market Restraint Analysis
3.2.2.1. Regulations in new drug development
3.2.2.2. Pricing pressure
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. Analysis of total number of clinical trial studies conducted, by countries
3.3.4. Cost breakdown analysis for CRO's
3.3.5. Percent of outsourced vs in-house clinical trial categories
3.3.6. Cost breakdown analysis for CRO's by Phase I, II, & III
3.3.7. COVID-19 Impact Analysis
Chapter 4. Europe Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Europe Clinical Trials Market, Phase Movement Analysis
4.3. Europe Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
4.4. Phase I
4.4.1. Phase I Market, 2018 to 2030 (USD Million)
4.5. Phase II
4.5.1. Phase II Market, 2018 to 2030 (USD Million)
4.6. Phase III
4.6.1. Phase III Market, 2018 to 2030 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market, 2018 to 2030 (USD Million)
Chapter 5. Europe Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Europe Clinical Trials Market, Study Design Movement Analysis
5.3. Europe Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
5.4. Interventional studies
5.4.1. Interventional Studies Market, 2018 to 2030 (USD Million)
5.5. Observational studies
5.5.1. Observational Studies Market, 2018 to 2030 (USD Million)
5.6. Expanded access studies
5.6.1. Expanded Access Studies Market, 2018 to 2030 (USD Million)
Chapter 6. Europe Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Europe Clinical Trials Market, Indication Movement Analysis
6.3. Europe Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Autoimmune/inflammation
6.4.1. Autoimmune/Inflammation Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome (IBS)
6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain Management
6.5.1. Pain Management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic Pain
6.5.2.1. Chronic Pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute Pain
6.5.3.1. Acute Pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood Cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid Tumors
6.6.3.1. Solid Tumors Market, 2018 to 2030 (USD Million)
6.6.4. Other
6.6.4.1. Other Market, 2018 to 2030 (USD Million)
6.7. CNS conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's Disease (PD)
6.7.3.1. Parkinson's Disease (PD) Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's Disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Traumatic Brain Injury (TBI)
6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 to 2030 (USD Million)
6.7.7. Amyotrophic Lateral Sclerosis (ALS)
6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.8. Muscle Regeneration
6.7.8.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.9. Others
6.7.9.1. Other Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Cardiovascular
6.10.1. Cardiovascular Market, 2018 to 2030 (USD Million)
6.11. Others
6.11.1. Others Market, 2018 to 2030 (USD Million)
Chapter 7. Europe Clinical Trials Market: Service Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Europe Clinical Trials Market, Service Type Movement Analysis
7.3. Europe Clinical Trials Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
7.4. Protocol Designing
7.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
7.5. Site Identification
7.5.1. Site Identification Market, 2018 to 2030 (USD Million)
7.6. Patient Recruitment
7.6.1. Patient Recruitment Market, 2018 to 2030 (USD Million)
7.7. Laboratory Services
7.7.1. Laboratory Services Market, 2018 to 2030 (USD Million)
7.8. Bioanalytical Testing Services
7.8.1. Bioanalytical Testing Services Market, 2018 to 2030 (USD Million)
7.9. Clinical Trial Data Management Services
7.9.1. Clinical Trial Data Management Services Market, 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others Market, 2018 to 2030 (USD Million)
Chapter 8. Europe Clinical Trials Market: Sponsor Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Europe Clinical Trials Market, Sponsor Movement Analysis
8.3. Europe Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & biopharmaceutical companies
8.4.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.5. Medical device companies
8.5.1. Protocol Designing Market, 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Others Market, 2018 to 2030 (USD Million)
Chapter 9. Europe Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. Europe
9.3.1. Europe Market Estimates and Forecast, 2018-2030 (Revenue, USD Million)
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Framework
9.3.2.4. UK Market Estimates and Forecasts, 2018-2030
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Germany Market Estimates and Forecasts, 2018-2030
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. France Market Estimates and Forecasts, 2018-2030
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Italy Market Estimates and Forecasts, 2018-2030
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Spain Market Estimates and Forecasts, 2018-2030
9.3.7. Sweden
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Sweden Market Estimates and Forecasts, 2018-2030
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Denmark Market Estimates and Forecasts, 2018-2030
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Norway Market Estimates and Forecasts, 2018-2030
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Company Market Position Analysis, 2023
10.3. Company Profiles
10.3.1. IQVIA Holdings, Inc.,
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Parexel International Corporation
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. PPD, Inc.
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Syneos Health
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Eli Lilly and Company
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Novo Nordisk A/S
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer, Inc.
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Dr. Notghi Contract Research GmbH
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Charite Research Organisation GmbH
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Janssen Global Services, LLC
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. KFGN
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Clariness
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Invisio Clinical Studies Consulting GmbH
10.3.13.1. Company Overview
10.3.13.2. Financial Performance
10.3.13.3. Service Benchmarking
10.3.13.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 1 List of Abbreviations
Table 2 Europe Clinical Trials, by Country, 2018 - 2030 (USD Million)
Table 3 Europe Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 4 Europe Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 5 Europe Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 6 Europe Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 7 Europe Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 8 UK Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 9 UK Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 10 UK Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 11 UK Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 12 UK Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 13 Germany Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 14 Germany Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 15 Germany Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 16 Germany Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 17 Germany Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 18 France Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 19 France Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 20 France Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 21 France Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 22 France Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 23 Italy Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 24 Italy Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 25 Italy Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 26 Italy Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 27 Italy Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 28 Spain Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 29 Spain Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 30 Spain Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 31 Spain Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 32 Spain Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 33 Sweden Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 34 Sweden Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 35 Sweden Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 36 Sweden Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 37 Sweden Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 38 Denmark Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 39 Denmark Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 40 Denmark Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 41 Denmark Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 42 Denmark Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
Table 43 Norway Clinical Trials, by Phase, 2018 - 2030 (USD Million)
Table 44 Norway Clinical Trials, by Study design, 2018 - 2030 (USD Million)
Table 45 Norway Clinical Trials, by Indication, 2018 - 2030 (USD Million)
Table 46 Norway Clinical Trials, by Service Type, 2018 - 2030 (USD Million)
Table 47 Norway Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Europe Clinical Trials Market revenue, 2018 - 2030 (USD Million)
Fig. 10 Europe Clinical Trials Market snapshot
Fig. 11 Europe Clinical Trials Market Driver Impact
Fig. 12 Europe Clinical Trials Market Restraint impact
Fig. 13 Europe Clinical Trials Market: Phase Key Takeaways (USD Million)
Fig. 14 Europe Clinical Trials Market: Phase movement analysis
Fig. 15 Phase I Market, 2018 - 2030 (USD Million)
Fig. 16 Phase II Market, 2018 - 2030 (USD Million)
Fig. 17 Phase III Market, 2018 - 2030 (USD Million)
Fig. 18 Phase IV Market, 2018 - 2030 (USD Million)
Fig. 19 Europe Clinical Trials Product Market: Study Design Key Takeaways (USD Million)
Fig. 20 Europe Clinical Trials Market: Study design movement analysis
Fig. 21 Interventional Studies Market, 2018 - 2030 (USD Million)
Fig. 22 Observational Studies Market, 2018 - 2030 (USD Million)
Fig. 23 Expanded access studies Market, 2018 - 2030 (USD Million)
Fig. 24 Europe Clinical Trials Market: Indication Key Takeaways (USD Million)
Fig. 25 Europe Clinical Trials Market: Indication movement analysis
Fig. 26 Autoimmune/Inflammation Market, 2018 - 2030 (USD Million)
Fig. 27 Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
Fig. 28 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
Fig. 29 Osteoarthritis Market, 2018 - 2030 (USD Million)
Fig. 30 Irritable Bowel Syndrome (IBS) Market, 2018 - 2030 (USD Million)
Fig. 31 Others Market, 2018 - 2030 (USD Million)
Fig. 32 Pain Management Market, 2018 - 2030 (USD Million)
Fig. 33 Chronic pain Market, 2018 - 2030 (USD Million)
Fig. 34 Acute pain Market, 2018 - 2030 (USD Million)
Fig. 35 Oncology Market, 2018 - 2030 (USD Million)
Fig. 36 Blood Cancer Market, 2018 - 2030 (USD Million)
Fig. 37 Solid Tumors Market, 2018 - 2030 (USD Million)
Fig. 38 Other Market, 2018 - 2030 (USD Million)
Fig. 39 CNS conditions Market, 2018 - 2030 (USD Million)
Fig. 40 Epilepsy Market, 2018 - 2030 (USD Million)
Fig. 41 Parkinson's Disease (PD) Market, 2018 - 2030 (USD Million)
Fig. 42 Huntington's Disease Market, 2018 - 2030 (USD Million)
Fig. 43 Stroke Market, 2018 - 2030 (USD Million)
Fig. 44 Traumatic Brain Injury (TBI) Market, 2018 - 2030 (USD Million)
Fig. 45 Amyotrophic Lateral Sclerosis (ALS) Market, 2018 - 2030 (USD Million)
Fig. 46 Muscle regeneration Market, 2018 - 2030 (USD Million)
Fig. 47 Others Market, 2018 - 2030 (USD Million)
Fig. 48 Diabetes Market, 2018 - 2030 (USD Million)
Fig. 49 Obesity Market, 2018 - 2030 (USD Million)
Fig. 50 Cardiovascular Market, 2018 - 2030 (USD Million)
Fig. 51 Others Market, 2018 - 2030 (USD Million)
Fig. 52 Europe Clinical Trials Market: Service Type Key Takeaways (USD Million)
Fig. 53 Europe Clinical Trials Market: Service Type movement analysis
Fig. 54 Protocol Designing Market, 2018 - 2030 (USD Million)
Fig. 55 Site Identification Market, 2018 - 2030 (USD Million)
Fig. 56 Patient Recruitment Market, 2018 - 2030 (USD Million)
Fig. 57 Laboratory Services Market, 2018 - 2030 (USD Million)
Fig. 58 Bioanalytical Testing Services Market, 2018 - 2030 (USD Million)
Fig. 59 Clinical Trial Data Management Services Market, 2018 - 2030 (USD Million)
Fig. 60 Others Market, 2018 - 2030 (USD Million)
Fig. 61 Europe Clinical Trials Market: Sponsor Key Takeaways (USD Million)
Fig. 62 Europe Clinical Trials Market: Sponsor movement analysis
Fig. 63 Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
Fig. 64 Medical Device Companies Market, 2018 - 2030 (USD Million)
Fig. 65 Others Market, 2018 - 2030 (USD Million)
Fig. 66 Europe Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 67 UK Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 68 Germany Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 69 France Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 70 Italy Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 71 Spain companion animal Health market, 2018 - 2030 (USD Million)
Fig. 72 Sweden Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 73 Denmark Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 74 Norway Clinical Trials Market, 2018 - 2030 (USD Million)
Fig. 75 Market participant categorization